



Europass Curriculum Vitae



Personal information

First name(s) / Surname(s)

Ilaria Del Giudice

Address(es)

Hematology, Department of Cellular Biotechnologies and Hematology
Sapienza University of Rome
Via Benevento 6
00161 Rome (Italy)

Telephone(s)

Lab +39 06 441639817
Mobile +39 339 5277930

Fax(es)

+39 06 44241984

E-mail

delgiudice@bce.uniroma1.it; idelgiu@gmail.com; idelgiu@pec.it

Nationality

Italian

Date of birth

14/10/1971

Gender

F

Occupational field

Clinical and translational research in Hematology (MED/15)

Work experience

20 March 2017 – at present. Temporary Assistant Professor at the Division of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome. RTD-B MED/15 SSD 06/D3.

1 February 2017 – 20 March 2017. Temporary Assistant Professor at the Division of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome. RTD-A MED/15 SSD 06/D3.

1 June 2011 – 31 May 2016. Temporary Assistant Professor at the Division of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome. RTD MED/15 (art. 1, comma 14, legge 4 novembre 2005, n. 230), funded by the project: Special Program Molecular Clinical Oncology 5x1000 AIRC n.10007 (PI: Prof. R. Foà): translational research activity on diagnostic and prognostic markers of chronic lymphoproliferative disorders.

10 April 2015 – 31 May 2016. UOC of Ematologia, DAI Ematologia, Oncologia, Anatomia Patologica e Medicina Rigenerativa, Azienda Policlinico Umberto I, Rome. Hematologist, clinical activity: morphologic diagnosis of onco-hematologic diseases.

March 2006 – May 2011. Contract as Hematologist at the UOC of Ematologia, Azienda Policlinico Umberto I, Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome: clinical activity with patients affected by chronic lymphoproliferative disorders and autoimmune hemolytic anemia and management of phase I, II and III clinical trials; research activity in projects on diagnostic and prognostic markers of chronic lymphoproliferative disorders.

November 2001- October 2005. Ph.D. student in Hematological Sciences (XVII cycle), Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome (Prof. R. Foà').

During this period (May 2002-December 2004), scholarship from the British Journal of Haematology Research Fund for overseas scientists/clinicians: research activity on the diagnosis of chronic lymphoproliferative disorders integrating morphology, flow cytometry, histopathology, FISH at the Academic Department of Haematology and Cytogenetics (Prof. Daniel Catovsky, Dr. Estela Matutes) of the Royal Marsden Hospital/Institute of Cancer Research (London, UK); clinical activity with outpatients affected by chronic lymphocytic leukemia, hairy cell leukemia and other chronic lymphoproliferative disorders.

2000-2001. Works as Hematologist in the Pediatric Hematology Unit and Day-Hospital, Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome.

February-May 1998. Attends for a clinical stage the St Jude Children Research Hospital of Memphis (Tennessee, US), Bone Marrow Transplantation Unit (Dr. L. Bowman) and Pediatric Hematology Unit (Dr. C.H. Pui).

1996-2000. Works as Resident in Hematology in the Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome (Prof. F. Mandelli), in the Pediatric Unit with children affected by acute leukemias and non-Hodgkin lymphomas, receiving chemotherapy and bone marrow transplantation.

1994-1996. Attends as a medical student the Pediatric Unit of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome.

Occupation or position held

Temporary Assistant Professor (RTD-B MED/15 SSD 06/D3) from March 20th, 2017, Sapienza University of Rome.

Main activities and responsibilities Clinical activity: diagnosis of onco-hematologic diseases.
 Research activity: translational research on diagnostic and prognostic markers of chronic lymphoproliferative disorders. Current research activity is focused on: i) the mechanisms of resistance and clonal evolution of CLL with mutated or wild-type *TP53* gene in patients treated with immunochemotherapy or B-cell receptors inhibitors within GIMEMA national trials; ii) minimal residual disease (MRD) as a tool to personalize CLL and NHL therapy; iii) the genetics of non-progressive/highly stable CLL.
 Teaching activity:
 Since 2012/2013, Malattie del Sangue, Corso di Laurea "G" Tecniche di Radiologia Medica per Immagini e Radioterapia, Facoltà di Farmacia e Medicina, Ospedale S. Spirito, Sapienza University, Rome
 Since 2013/2014, Malattie del Sangue, Corso di Laurea "C" Tecniche di Radiologia Medica per Immagini e Radioterapia della Facoltà di Farmacia ed Odontoiatria, Sapienza University (Sabina Universitas, Rieti)
 Since 2013/2014, Malattie del Sangue, Corso di Laurea "F" Tecniche di laboratorio biomedico della Facoltà di Farmacia e Odontoiatria, Sapienza University (Sabina Universitas, Rieti)
 Since 2013/2014, Practical training and tutorial activities, Ematologia (C.I. Patologia Integrata IV), Corso di Laurea A in Medicina e Chirurgia, Facoltà di Farmacia e Medicina, Sapienza University, Rome
 Since 2013, member of Collegio docenti del dottorato SIER (Scienze Immunologiche, Ematologiche, Reumatologiche), Sapienza University, Rome
 Tutor and thesis supervisor of medical students (Percorso di Eccellenza), PhD students and fellows in Hematology, Sapienza University, Rome

Name and address of employer Sapienza University, Division of Hematology, Dept of Cellular Biotechnologies and Hematology, Via Benevento, 6, 00161 Rome (Italy)
Sector Hematology

Education and training **29 May 2006:** PhD in Hematological Science (XVII cycle) at Sapienza University of Rome.
 Title of dissertation: "Biologic characterization of chronic lymphoproliferative disorders: study of novel markers with diagnostic/prognostic significance".
11 December 2000: Specialist training accreditation in Hematology with highest honors at Sapienza University of Rome (70/70 cum laude). Title of dissertation: "A single high dose of Idarubicin combined with high dose of ARA-C for treatment of first relapse in childhood acute lymphoblastic leukemia".
May 1997: Professional licence at Sapienza University of Rome.
2 October 1996: Degree in Medicine with highest honors at Sapienza University of Rome (110/110 cum laude). Title of dissertation: "Acute lymphoblastic leukemia in childhood: long-term follow-up in patients treated c/o Department of Hematology, "La Sapienza" University of Rome with three consecutive protocols from 1972 to 1988".

Title of qualification awarded MD, PhD
Name and type of organisation providing education and training Sapienza University of Rome, Italy

Personal skills and competences Design of translational research projects. Cell morphology and immunophenotype.

Mother tongue(s) Italian

Other language(s) English

Self-assessment
European level ()*

Language

Understanding		Speaking		Writing	
Listening	Reading	Spoken interaction	Spoken production		
C2	C2	C2	C2	C2	

(*) [Common European Framework of Reference for Languages](#)

Additional information Member of EHA (European Hematology Association) and ERIC (European Research Initiative on Chronic Lymphocytic Leukemia-CLL). Member of the Commissione Studi Biologici and the MRD network of the Fondazione Italiana Linfomi (FIL).
 Reviewer for the following journals: Blood, British Journal of Haematology, American Journal of Haematology, Haematologica, Lancet Hematology.

Annexes

Attends regularly the EHA (European Hematology Association) and ASH (American Society of Hematology) annual congresses and SIES (Società Italiana di Ematologia Sperimentale) congresses

Textbooks (Chapters, etc.)

Coauthor of the following textbooks:

Manuale di Ematologia, editori proff. P. Corradini and R. Foà, Edizioni Minerva Medica, writing the chapter on Disordini Linfoproliferativi Cronici (with Prof. R. Foà and Dr. F.R. Mauro), first edition 2008; second edition 2014.

Le micosi invasive nell'ospite immunocompromesso, by proff. P. Serra and F. Mandelli, Edizioni Carocci Faber, writing the chapter on Nuove terapie in oncoematologia e nuovi fattori di rischio infettivi (with Prof. R. Foà).

In 2010, she wrote, together with Prof. R. Foà, some hematology contributions for the Dizionario di Medicina of the Enciclopedia Treccani. In 2014, the chapter on Leukemias of the IX appendix of the Enciclopedia Treccani. She contributed, with Prof. R. Foà, to the Italian translation of some hematology chapters of the book Harrison's Principles of Internal Medicine, 19^o ed. 2015, McGraw-Hill for the Casa Editrice Ambrosiana (Zanichelli Editore).

Scientific Publication

- 1) **Del Giudice I**, Marinelli M, Wang J, Bonina S, Messina M, Chiaretti S, Ilari C, Cafforio L, Raponi S, Mauro FR, Di Maio V, De Propriis MS, Nanni M, Ciardullo C, Rossi D, Gaidano G, Guarini A, Rabadan R, Foà R. Inter- and intra-patient clonal and subclonal heterogeneity of chronic lymphocytic leukaemia: evidences from circulating and lymph nodal compartments. *Br J Haematol*. 2016 Feb;172(3):371-83. doi: 10.1111/bjh.13859. Epub 2015 Nov 24. PubMed PMID: 26597680; PubMed Central PMCID: PMC4732889. **IF 2015: 5.401**
- 2) Rigolin GM, **Del Giudice I**, Formigaro L, Saccenti E, Martinelli S, Cavallari M, Lista E, Tammiso E, Volta E, Lupini L, Bassi C, Bardi A, Soffritti O, Daghia G, Cavazzini F, Marinelli M, Tavolaro S, Guarini A, Negrini M, Foà R, Cuneo A. Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations. *Genes Chromosomes Cancer*. 2015 Dec;54(12):818-26. doi: 10.1002/gcc.22293. Epub 2015 Sep 10. PubMed PMID: 26355802. **IF 2015: 3.960**
- 3) Rossi D, Terzi-di-Bergamo L, De Paoli L, Cerri M, Ghilardi G, Chiarenza A, Bulian P, Visco C, Mauro FR, Morabito F, Cortelezzi A, Zaja F, Forconi F, Laurenti L, **Del Giudice I**, Gentile M, Vincelli I, Motta M, Coscia M, Rigolin GM, Tedeschi A, Neri A, Marasca R, Perbellini O, Moreno C, Del Poeta G, Massaia M, Zinzani PL, Montillo M, Cuneo A, Gattei V, Foà R, Gaidano G. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. *Blood*. 2015 Oct 15;126(16):1921-4. doi:10.1182/blood-2015-05-647925. Epub 2015 Aug 14. PubMed PMID: 26276669; PubMed Central PMCID: PMC4743433. **IF 2015: 11.841**
- 4) Galimberti S, Luminari S, Ciabatti E, Grassi S, Guerrini F, Dondi A, Marcheselli L, Ladetto M, Piccaluga PP, Gazzola A, Mannu C, Monitillo L, Mantoan B, **Del Giudice I**, Della Starza I, Cavalli M, Arcaini L, Tucci A, Palumbo GA, Rigacci L, Pulsoni A, Vitolo U, Boccomini C, Vallisa D, Bertoldo G, Gaidano G, Musto P, Petrini M, Federico M. Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial. *Clin Cancer Res*. 2014 Dec 15;20(24):6398-405. doi: 10.1158/1078-0432.CCR-14-0407. Epub 2014 Oct 14. PubMed PMID: 25316810. **IF 2015: 8.738**
- 5) Messina M, **Del Giudice I**, Khiabani H, Rossi D, Chiaretti S, Rasi S, Spina V, Holmes AB, Marinelli M, Fabbri G, Piciocchi A, Mauro FR, Guarini A, Gaidano G, Dalla-Favera R, Pasqualucci L, Rabadan R, Foà R. Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness. *Blood*. 2014 Apr 10;123(15):2378-88. doi: 10.1182/blood-2013-10-534271. Epub 2014 Feb 18. PubMed PMID: 24550227; PubMed Central PMCID: PMC3983613. **IF 2015: 11.841**
- 6) Foà R, **Del Giudice I**, Cuneo A, Del Poeta G, Ciolli S, Di Raimondo F, Lauria F, Cencini E, Rigolin GM, Cortelezzi A, Nobile F, Callea V, Brugiattelli M, Massaia M, Molica S, Trentin L, Rizzi R, Specchia G, Di Serio F, Orsucci L, Ambrosetti A, Montillo M, Zinzani PL, Ferrara F, Morabito F, Mura MA, Soriani S, Peragine N, Tavolaro S, Bonina S, Marinelli M, De Propriis MS, Starza ID, Piciocchi A, Alietti A, Runggdier EJ, Gamba E, Mauro FR, Chiaretti S, Guarini A. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. *Am J Hematol*. 2014 May;89(5):480-6. doi: 10.1002/ajh.23668. Epub 2014 Feb 18. PubMed PMID: 24415640. **IF 2015: 5.000**
- 7) **Del Giudice I**, Chiaretti S, Santangelo S, Tavolaro S, Peragine N, Marinelli M, Ilari C, Raponi S, Messina M, Nanni M, Mauro FR, Piciocchi A, Bontempi K, Rossi D, Gaidano G, Guarini A, Foà R. Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between B-cell receptor structure, function, and patients' prognosis. *Am J Hematol*. 2014 Jan;89(1):74-82. PubMed PMID: 24030933. **IF 2015: 5.000**
- 8) Foà R, **Del Giudice I**, Guarini A, Rossi D, Gaidano G. Clinical implications of the molecular genetics of chronic lymphocytic leukemia. *Haematologica*. 2013 May;98(5):675-85. doi: 10.3324/haematol.2012.069369. Review. PubMed PMID: 23633543; PubMed Central PMCID: PMC3640109. **IF 2015: 6.671**
- 9) Knauf WU, Lissitchkov T, Aldaoud A, Liberati AM, Loscertales J, Herbrecht R, Juliusson G, Postner G, Gercheva L, Goranov S, Becker M, Fricke HJ, Huguet F, **Del Giudice I**, Klein P, Merkle K, Montillo M. Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial. *Br J Haematol*. 2012 Oct;159(1):67-77. doi: 10.1111/bjh.12000. Epub 2012 Aug 4. PubMed PMID: 22861163. **IF 2015: 5.401**

- 10) Rossi D, Fangazio M, Rasi S, Vaisitti T, Monti S, Cresta S, Chiaretti S, **Del Giudice I**, Fabbri G, Bruscazzin A, Spina V, Deambrogi C, Marinelli M, Famà R, Greco M, Daniele G, Forconi F, Gattei V, Bertoni F, Deaglio S, Pasqualucci L, Guarini A, Dalla-Favera R, Foà R, Gaidano G. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. *Blood*. 2012 Mar 22;119(12):2854-62. doi: 10.1182/blood-2011-12-395673. Epub 2012 Feb 3. PubMed PMID: 22308293. **IF 2015: 11.841 Cit tot: 112 contemporary H-index: 89.6**
- 11) **Del Giudice I**, Rossi D, Chiaretti S, Marinelli M, Tavorolo S, Gabrielli S, Laurenti L, Marasca R, Rasi S, Fangazio M, Guarini A, Gaidano G, Foà R. NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL. *Haematologica*. 2012 Mar;97(3):437-41. doi: 10.3324/haematol.2011.060129. Epub 2011 Dec 29. PubMed PMID: 22207691; PubMed Central PMCID: PMC3291600. **IF 2015: 6.671**
- 12) **Del Giudice I**, Messina M, Chiaretti S, Santangelo S, Tavorolo S, De Propriis MS, Nanni M, Pescarmona E, Mancini F, Pulsoni A, Martelli M, Di Rocco A, Finolezzi E, Paoloni F, Cuneo A, Guarini A, Foà R. Behind the scenes of non-nodal MCL: downmodulation of genes involved in actin cytoskeleton organization, cell projection, cell adhesion, tumour invasion, TP53 pathway and mutated status of immunoglobulin heavy chain genes. *Br J Haematol*. 2012 Mar;156(5):601-11. doi: 10.1111/j.1365-2141.2011.08962.x. Epub 2011 Dec 8. PubMed PMID: 22150124. **IF 2015: 5.401**
- 13) Guarini A, Marinelli M, Tavorolo S, Bellacchio E, Magliozzi M, Chiaretti S, De Propriis MS, Peragine N, Santangelo S, Paoloni F, Nanni M, **Del Giudice I**, Mauro FR, Torrente I, Foà R. ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression. *Haematologica*. 2012 Jan;97(1):47-55. doi:10.3324/haematol.2011.049270. Epub 2011 Oct 11. PubMed PMID: 21993670; PubMed Central PMCID: PMC3248930. **IF 2015: 6.671**
- 14) Rossi D, Bruscazzin A, Spina V, Rasi S, Khiabani H, Messina M, Fangazio M, Vaisitti T, Monti S, Chiaretti S, Guarini A, **Del Giudice I**, Cerri M, Cresta S, Deambrogi C, Gargiulo E, Gattei V, Forconi F, Bertoni F, Deaglio S, Rabadan R, Pasqualucci L, Foà R, Dalla-Favera R, Gaidano G. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. *Blood*. 2011 Dec 22;118(26):6904-8. doi: 10.1182/blood-2011-08-373159. Epub 2011 Oct 28. PubMed PMID: 22039264; PubMed Central PMCID: PMC3245210. **IF 2015: 11.841**
- 15) **Del Giudice I**, Mauro FR, Foà R. Chronic lymphocytic leukemia in less fit patients: "slow-go". *Leuk Lymphoma*. 2011 Dec;52(12):2207-16. doi:10.3109/10428194.2011.606386. Epub 2011 Sep 13. Review. PubMed PMID: 21774745. **IF 2015: 3.093**
- 16) Dal Bo M, Rossi FM, Rossi D, Deambrogi C, Bertoni F, **Del Giudice I**, Palumbo G, Nanni M, Rinaldi A, Kwee I, Tissino E, Corradini G, Gozzetti A, Cencini E, Ladetto M, Coletta AM, Luciano F, Bulian P, Pozzato G, Laurenti L, Forconi F, Di Raimondo F, Marasca R, Del Poeta G, Gaidano G, Foà R, Guarini A, Gattei V. 13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. *Genes Chromosomes Cancer*. 2011 Aug;50(8):633-43. doi: 10.1002/gcc.20885. Epub 2011 May 11. PubMed PMID: 21563234. **IF 2015: 3.960**
- 17) **Del Giudice I**, Mauro FR, De Propriis MS, Santangelo S, Marinelli M, Peragine N, Di Maio V, Nanni M, Barzotti R, Mancini F, Armiento D, Paoloni F, Guarini A, Foà R. White blood cell count at diagnosis and immunoglobulin variable region gene mutations are independent predictors of treatment-free survival in young patients with stage A chronic lymphocytic leukemia. *Haematologica*. 2011 Apr;96(4):626-30. doi: 10.3324/haematol.2010.028779. Epub 2010 Dec 29. PubMed PMID: 21193417; PubMed Central PMCID: PMC3069243. **IF 2015: 6.671**
- 18) **Del Giudice I**, Mauro FR, De Propriis MS, Starza ID, Armiento D, Iori AP, Torelli GF, Guarini A, Foà R. Identification of monoclonal B-cell lymphocytosis among sibling transplant donors for chronic lymphocytic leukemia patients. *Blood*. 2009 Sep 24;114(13):2848-9. doi: 10.1182/blood-2009-06-228395. PubMed PMID: 19779049. **IF 2015: 11.841**
- 19) Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R, Juliusson G, Postner G, Gercheva L, Goranov S, Becker M, Fricke HJ, Huguet F, **Del Giudice I**, Klein P, Tremmel L, Merkle K, Montillo M. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. *J Clin Oncol*. 2009 Sep 10;27(26):4378-84. doi:10.1200/JCO.2008.20.8389. Epub 2009 Aug 3. PubMed PMID: 19652068. **IF 2015: 20.982**
- 20) **Del Giudice I**, Osuji N, Dexter T, Brito-Babapulle V, Parry-Jones N, Chiaretti S, Messina M, Morgan G, Catovsky D, Matutes E. B-cell prolymphocytic leukemia and chronic lymphocytic leukemia have distinctive gene expression signatures. *Leukemia*. 2009 Nov;23(11):2160-7. doi: 10.1038/leu.2009.137. Epub 2009 Jul 30. PubMed PMID: 19641528. **IF 2015: 12.104**
- 21) **Del Giudice I**, Chiaretti S, Tavorolo S, De Propriis MS, Maggio R, Mancini F, Peragine N, Santangelo S, Marinelli M, Mauro FR, Guarini A, Foà R. Spontaneous regression of chronic lymphocytic leukemia: clinical and biologic features of 9 cases. *Blood*. 2009 Jul 16;114(3):638-46. doi: 10.1182/blood-2008-12-196568. Epub 2009 Apr 22. PubMed PMID: 19387007. **IF 2015: 11.841**
- 22) **Del Giudice I**, Pileri SA, Rossi M, Sabattini E, Campidelli C, Starza ID, De Propriis MS, Mancini F, Perrone MP, Gesuiti P, Armiento D, Quattrocchi L, Tafuri A, Amendola A, Mauro FR, Guarini A, Foà R. Histopathological and molecular features of persistent polyclonal B-cell lymphocytosis (PPBL) with progressive splenomegaly. *Br J Haematol*. 2009 Mar;144(5):726-31. doi:10.1111/j.1365-2141.2008.07551.x. Epub 2008 Dec 26. PubMed PMID: 19133977. **IF 2015: 5.401**

- 23) Guarini A, Chiaretti S, Tavolaro S, Maggio R, Peragine N, Citarella F, Ricciardi MR, Santangelo S, Marinelli M, De Propriis MS, Messina M, Mauro FR, **Del Giudice I**, Foà R. BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells. *Blood*. 2008 Aug 1;112(3):782-92. doi: 10.1182/blood-2007-12-127688. Epub 2008 May 16. PubMed PMID: 18487510. **IF 2015: 11.841**
- 24) Osuji N, Matutes E, Tjonnfjord G, Grech H, **Del Giudice I**, Wotherspoon A, Swansbury JG, Catovsky D. T-cell large granular lymphocyte leukemia: A report on the treatment of 29 patients and a review of the literature. *Cancer*. 2006 Aug 1;107(3):570-8. Review. Erratum in: *Cancer*. 2006 Dec 1;107(11):2744. PubMed PMID:16795070. **IF 2015: 5.649**
- 25) **Del Giudice I**, Davis Z, Matutes E, Osuji N, Parry-Jones N, Morilla A, Brito-Babapulle V, Oscier D, Catovsky D. IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL). *Leukemia*. 2006 Jul;20(7):1231-7. Epub 2006 Apr 27. PubMed PMID:16642047. **IF 2015: 12.104**
- 26) Else M, Ruchlemer R, Osuji N, **Del Giudice I**, Matutes E, Woodman A, Wotherspoon A, Swansbury J, Dearden C, Catovsky D. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years. *Cancer*. 2005 Dec 1;104(11):2442-8. PubMed PMID: 16245328. **IF 2015: 5.649**
- 27) Osuji NC, **Del Giudice I**, Matutes E, Wotherspoon AC, Dearden C, Catovsky D. The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. *Haematologica*. 2005 Oct;90(10):1435-6. Review. PubMed PMID: 16219582. **IF 2015: 6.671**
- 28) **Del Giudice I**, Morilla A, Osuji N, Matutes E, Morilla R, Burford A, Maravelaki S, Owusu-Ankomah K, Swansbury J, A'Hern R, Brito-Babapulle V, Catovsky D. Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia. *Cancer*. 2005 Nov 15;104(10):2124-32. PubMed PMID: 16211545. **IF 2015: 5.649**
- 29) **Del Giudice I**, Matutes E, Morilla R, Morilla A, Owusu-Ankomah K, Rafiq F, A'Hern R, Delgado J, Bazerbashi MB, Catovsky D. The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes. *Haematologica*. 2004 Mar;89(3):303-8. PubMed PMID: 15020268. **IF 2015: 6.671**
- 30) **Del Giudice I**, Iori AP, Mengarelli A, Testi AM, Romano A, Cerretti R, Macri F, Iacobini M, Arcese W. Allogeneic stem cell transplant from HLA-identical sibling for chronic granulomatous disease and review of the literature. *Ann Hematol*. 2003 Mar;82(3):189-92. Epub 2003 Feb 12. Review. PubMed PMID: 12634956. **IF 2015: 3.022**

Rome, 24 March 2017